DK1254899T3 - Piperazinderivater og deres anvendelse som anti-inflammatoriske midler - Google Patents

Piperazinderivater og deres anvendelse som anti-inflammatoriske midler

Info

Publication number
DK1254899T3
DK1254899T3 DK02090193T DK02090193T DK1254899T3 DK 1254899 T3 DK1254899 T3 DK 1254899T3 DK 02090193 T DK02090193 T DK 02090193T DK 02090193 T DK02090193 T DK 02090193T DK 1254899 T3 DK1254899 T3 DK 1254899T3
Authority
DK
Denmark
Prior art keywords
inflammatory agents
piperazine derivatives
compounds
directed
humans
Prior art date
Application number
DK02090193T
Other languages
Danish (da)
English (en)
Inventor
Brad O Buckman
Josep E Hesselgasser
Richard Horuk
Imadul Islam
Meina Liang
Karen B May
Michael M Morissey
Howarfd P Ng
Wie Xu
Wie Zheng
Kenneth J Shaw
Zhao Zuchun
John G Bauman
Ameen F Ghannam
Sean D Monahan
Gua Ping Wei
Original Assignee
Schering Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Ag filed Critical Schering Ag
Application granted granted Critical
Publication of DK1254899T3 publication Critical patent/DK1254899T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
    • C07D295/18—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carboxylic acids, or sulfur or nitrogen analogues thereof
    • C07D295/182—Radicals derived from carboxylic acids
    • C07D295/185—Radicals derived from carboxylic acids from aliphatic carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/18—Halogen atoms or nitro radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/04—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/36—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems
    • C07D241/38—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems with only hydrogen or carbon atoms directly attached to the ring nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
    • C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
    • C07D261/10—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D261/14—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
    • C07D295/18—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carboxylic acids, or sulfur or nitrogen analogues thereof
    • C07D295/182—Radicals derived from carboxylic acids
    • C07D295/192—Radicals derived from carboxylic acids from aromatic carboxylic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D307/38—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D307/52—Radicals substituted by nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
DK02090193T 1997-06-12 1998-06-11 Piperazinderivater og deres anvendelse som anti-inflammatoriske midler DK1254899T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US87359997A 1997-06-12 1997-06-12
US09/094,397 US6207665B1 (en) 1997-06-12 1998-06-09 Piperazine derivatives and their use as anti-inflammatory agents
EP98937467A EP0988292B1 (fr) 1997-06-12 1998-06-11 Derives de piperazine et leur utilisation en tant qu'agents anti-inflammatoires

Publications (1)

Publication Number Publication Date
DK1254899T3 true DK1254899T3 (da) 2005-09-05

Family

ID=26788818

Family Applications (2)

Application Number Title Priority Date Filing Date
DK02090193T DK1254899T3 (da) 1997-06-12 1998-06-11 Piperazinderivater og deres anvendelse som anti-inflammatoriske midler
DK98937467T DK0988292T3 (da) 1997-06-12 1998-06-11 Piperazinderivater og deres anvendelse som antiinflammationsmidler

Family Applications After (1)

Application Number Title Priority Date Filing Date
DK98937467T DK0988292T3 (da) 1997-06-12 1998-06-11 Piperazinderivater og deres anvendelse som antiinflammationsmidler

Country Status (22)

Country Link
US (8) US6207665B1 (fr)
EP (2) EP0988292B1 (fr)
JP (1) JP2002503239A (fr)
KR (1) KR100549137B1 (fr)
AT (2) ATE296292T1 (fr)
AU (1) AU735462B2 (fr)
CA (1) CA2293382C (fr)
CZ (1) CZ295784B6 (fr)
DE (2) DE69811363T2 (fr)
DK (2) DK1254899T3 (fr)
EA (2) EA004038B1 (fr)
EE (4) EE200200683A (fr)
ES (2) ES2191320T3 (fr)
HU (1) HUP0003929A3 (fr)
IL (1) IL132398A (fr)
IS (1) IS2241B (fr)
NO (2) NO317343B1 (fr)
PL (1) PL337758A1 (fr)
PT (1) PT1254899E (fr)
SK (2) SK285162B6 (fr)
TR (1) TR199903034T2 (fr)
WO (1) WO1998056771A2 (fr)

Families Citing this family (95)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6207665B1 (en) * 1997-06-12 2001-03-27 Schering Aktiengesellschaft Piperazine derivatives and their use as anti-inflammatory agents
AU2740900A (en) * 1999-01-29 2000-08-18 Millennium Pharmaceuticals, Inc. Method of treating demyelinating inflammatory disease using ccr1 antagonists
EE200200567A (et) * 2000-03-31 2004-06-15 Pfizer Products Inc. Uued piperasiini derivaadid
US6740636B2 (en) * 2000-07-31 2004-05-25 Schering Aktiengesellschaft Non-peptide CCR1 receptor antagonists in combination with cyclosporin A for the treatment of heart transplant rejection
LT5132B (lt) 2000-07-31 2004-05-25 Schering Aktiengesellschaft Nepeptidiniai ccr1 receptorių antagonistai derinyje su ciklosporinu a širdies transplanto atmetimui gydyti
EP1578341A4 (fr) * 2000-10-11 2005-09-28 Tularik Inc Modulation de fonction de ccr4
MXPA03003475A (es) * 2000-10-19 2003-07-14 Pfizer Prod Inc Derivados puente de piperazina.
UY27003A1 (es) 2000-11-06 2002-07-31 Schering Ag Productos radiofarmacéuticos para el diagnóstico de la enfermedad de alzheimer
WO2002094264A1 (fr) * 2001-05-23 2002-11-28 Tularik Inc. Antagonistes de ccr4
US6861424B2 (en) * 2001-06-06 2005-03-01 Schering Aktiengesellschaft Platelet adenosine diphosphate receptor antagonists
US7253172B2 (en) * 2001-06-20 2007-08-07 Merck & Co., Inc. Dipeptidyl peptidase inhibitors for the treatment of diabetes
MXPA03011954A (es) 2001-06-20 2004-03-26 Pfizer Prod Inc Nuevos derivados de acido sulfonico.
US6812230B2 (en) * 2001-08-07 2004-11-02 Schering Aktiengesellschaft Non-peptide CCR1 receptor antagonists for the treatment of progressive renal fibrosis
US7354923B2 (en) * 2001-08-10 2008-04-08 Palatin Technologies, Inc. Piperazine melanocortin-specific compounds
US7655658B2 (en) * 2001-08-10 2010-02-02 Palatin Technologies, Inc. Thieno [2,3-D]pyrimidine-2,4-dione melanocortin-specific compounds
US7456184B2 (en) * 2003-05-01 2008-11-25 Palatin Technologies Inc. Melanocortin receptor-specific compounds
WO2003013571A1 (fr) * 2001-08-10 2003-02-20 Palatin Technologies, Inc. Peptidomimetiques de metallopeptides biologiquement actifs
US7718802B2 (en) 2001-08-10 2010-05-18 Palatin Technologies, Inc. Substituted melanocortin receptor-specific piperazine compounds
US7732451B2 (en) * 2001-08-10 2010-06-08 Palatin Technologies, Inc. Naphthalene-containing melanocortin receptor-specific small molecule
US20030087913A1 (en) * 2001-10-18 2003-05-08 Schering Ag Solid pharmaceutical agent formulation for a piperazine urea derivative
DE10152351B4 (de) * 2001-10-18 2005-09-22 Schering Ag Feste Arzneimittelformulierung für ein Piperazinharnstoffderivat
ES2337241T3 (es) * 2001-10-22 2010-04-22 Pfizer Products Inc. Derivados de piperazina con actividad antagonista de receptores ccr1.
KR100472086B1 (ko) * 2001-11-23 2005-02-21 한국화학연구원 항산화 활성을 갖는 3,5-디알콕시-4-히드록시페닐기로치환된 피페라진 유도체, 그의 제조방법 및 이를 포함하는약학적 조성물
GB0203299D0 (en) * 2002-02-12 2002-03-27 Glaxo Group Ltd Novel compounds
GB0207447D0 (en) * 2002-03-28 2002-05-08 Glaxo Group Ltd Novel compounds
TW200400035A (en) 2002-03-28 2004-01-01 Glaxo Group Ltd Novel compounds
US20050256130A1 (en) * 2002-06-12 2005-11-17 Chemocentryx, Inc. Substituted piperazines
US6727241B2 (en) 2002-06-12 2004-04-27 Chemocentryx Anti-inflammatory compositions and methods of use
US7589199B2 (en) 2002-06-12 2009-09-15 Chemocentryx, Inc. Substituted piperazines
DE60328690D1 (de) * 2002-06-12 2009-09-17 Chemocentryx Inc 1-aryl-4-substituierte piperazin-derivate zur verwendung als ccr1-antagonisten zur behandlung von entzündungen und immunerkrankungen
US7842693B2 (en) * 2002-06-12 2010-11-30 Chemocentryx, Inc. Substituted piperazines
US20040092529A1 (en) * 2002-10-30 2004-05-13 Pfizer Inc Methods of using piperazine derivatives
ES2348942T3 (es) 2002-12-11 2010-12-17 Bayer Schering Pharma Aktiengesellschaft Compuestos de 2-aminocarbonil-quinolina como antagonistas del receptor plaquetario de adenosin difosfato.
CA2505979A1 (fr) * 2002-12-13 2004-07-01 Pfizer Products Inc. Derives de piperazine contenant du phosphore en tant qu'antagonistres de ccr1
US7727991B2 (en) 2003-05-01 2010-06-01 Palatin Technologies, Inc. Substituted melanocortin receptor-specific single acyl piperazine compounds
US7968548B2 (en) 2003-05-01 2011-06-28 Palatin Technologies, Inc. Melanocortin receptor-specific piperazine compounds with diamine groups
US7727990B2 (en) 2003-05-01 2010-06-01 Palatin Technologies, Inc. Melanocortin receptor-specific piperazine and keto-piperazine compounds
WO2005102340A1 (fr) * 2003-05-30 2005-11-03 Palatin Technologies, Inc. Composes de piperazine specifiques de la melanocortine
WO2005018642A1 (fr) * 2003-08-22 2005-03-03 Schering Aktiengesellschaft Derives de piperazine inhibant les chimiokines et leur utilisation en traitement de myocardites
JP2007504123A (ja) 2003-08-29 2007-03-01 ランバクシー ラボラトリーズ リミテッド Ｉｖ型ホスホジエステラーゼの阻害剤
US8071134B2 (en) 2003-09-15 2011-12-06 Ordway Research Institute, Inc. Thyroid hormone analogs and methods of use
US7785632B2 (en) 2003-09-15 2010-08-31 Ordway Research Institute, Inc. Thyroid hormone analogs and methods of use
WO2006031922A2 (fr) 2004-09-15 2006-03-23 Ordway Research Institute Analogues d'hormones thyroidiennes et procedes d'utilisation correspondants
US9198887B2 (en) 2003-09-15 2015-12-01 Nanopharmaceuticals Llc Thyroid hormone analogs and methods of use
US8668926B1 (en) 2003-09-15 2014-03-11 Shaker A. Mousa Nanoparticle and polymer formulations for thyroid hormone analogs, antagonists, and formulations thereof
AU2005212290A1 (en) * 2004-02-06 2005-08-25 Schering Aktiengesellschaft Chemokine inhibiting piperazine derivatives and their use to treat multiple myeloma
BRPI0507985A (pt) * 2004-02-24 2007-05-08 Schering Aktiengellschaft derivados de piperazina uréia para o tratamento de endometriose
SE0400440D0 (sv) * 2004-02-25 2004-02-25 Active Biotech Ab Novel Cinnamic Amides
SE0400441D0 (sv) 2004-02-25 2004-02-25 Active Biotech Ab Novel Benzofurans and Indols
CA2558211C (fr) * 2004-03-03 2013-09-03 Chemocentryx, Inc. Heterocycles d'azote bicycliques et pontes
US7435831B2 (en) * 2004-03-03 2008-10-14 Chemocentryx, Inc. Bicyclic and bridged nitrogen heterocycles
US7709484B1 (en) 2004-04-19 2010-05-04 Palatin Technologies, Inc. Substituted melanocortin receptor-specific piperazine compounds
ES2251292B1 (es) * 2004-04-20 2007-07-01 Inke, S.A. Procedimiento para la obtencion de un compuesto farmaceuticamente activo y de sus intermedios de sintesis.
GB0409236D0 (en) * 2004-04-26 2004-05-26 Novartis Ag Organic compounds
EP1749519A1 (fr) 2005-08-05 2007-02-07 Schering Aktiengesellschaft Forme galénique à libération prolongée pH-indépendant pour les substances actives avec une solubilité pH-dépendante
US20070087056A1 (en) * 2005-08-09 2007-04-19 Claudia Guthmann Pharmaceutical form with sustained pH-independent active ingredient release for active ingredients having strong pH-dependent solubility
US9498536B2 (en) 2005-09-15 2016-11-22 Nanopharmaceuticals Llc Method and composition of thyroid hormone analogues and nanoformulations thereof for treating anti-inflammatory disorders
US10130686B2 (en) 2005-09-15 2018-11-20 Nanopharmaceuticals Llc Method and composition of thyroid hormone analogues and nanoformulations thereof for treating inflammatory disorders
WO2007035612A2 (fr) 2005-09-16 2007-03-29 Ordway Research Institute, Inc. Composes de liaison rgd et leurs procedes d'utilisation
AU2006319247B2 (en) * 2005-12-01 2010-03-11 F. Hoffmann-La Roche Ag Heteroaryl substituted piperidine derivatives as L-CPT1 inhibitors
CA2651732C (fr) * 2006-05-18 2014-10-14 Mannkind Corporation Inhibiteurs de kinases intracellulaires
FR2902426B1 (fr) * 2006-06-19 2008-09-05 Pierre Fabre Medicament Sa Derives de cinnamoyl-piperazine
US7834017B2 (en) 2006-08-11 2010-11-16 Palatin Technologies, Inc. Diamine-containing, tetra-substituted piperazine compounds having identical 1- and 4-substituents
PT2076508E (pt) 2006-10-18 2011-03-07 Pfizer Prod Inc Compostos de ureia de éter biarílico
ES2535005T3 (es) 2006-12-22 2015-05-04 Nanopharmaceuticals Llc Formulaciones de nanopartículas y de polímeros para análogos, antagonistas y formulaciones de la hormona tiroidea, y usos de los mismos
WO2008090357A2 (fr) * 2007-01-24 2008-07-31 Palatin Technologies, Inc. Composés à base de pipérazine spécifiques du récepteur de la mélanocortine
US20080207659A1 (en) 2007-02-15 2008-08-28 Asit Kumar Chakraborti Inhibitors of phosphodiesterase type 4
US9180107B2 (en) 2009-03-31 2015-11-10 Nanopharmaceuticals Llc Combination treatment of cancer with cetuximab and tetrac
WO2010148007A2 (fr) 2009-06-17 2010-12-23 Ordway Research Institute, Inc. Formulations nanoparticulaires et polymères pour hormone thyroïdienne, analogues, antagonistes et formulations et utilisations de celles-ci
HUE040420T2 (hu) 2010-03-11 2019-03-28 Univ New York Amidvegyületek, mint RORyT modulátorok és felhasználásuk
US8802240B2 (en) 2011-01-06 2014-08-12 Nanopharmaceuticals Llc Uses of formulations of thyroid hormone analogs and nanoparticulate forms thereof to increase chemosensitivity and radiosensitivity in tumor or cancer cells
KR101380466B1 (ko) * 2011-09-27 2014-04-02 한국생명공학연구원 ＨＩＦ―１α 활성을 저해하는 신규 화합물 및 그 제조방법
CN102408395B (zh) * 2011-10-24 2014-04-02 广西师范大学 新的哌嗪和高哌嗪类衍生物及其制备方法和应用
CA2852160A1 (fr) 2011-10-28 2013-05-02 Galderma Research & Development Nouveaux marqueurs d'infiltrat leucocytaire de rosacee et utilisations de ceux-ci
US20140221335A1 (en) 2013-02-06 2014-08-07 Boehringer Ingelheim International Gmbh Substituted bicyclic dihydropyrimidinones and their use as inhibitors of neutrophil elastase activity
US9115093B2 (en) 2013-03-04 2015-08-25 Boehringer Ingelheim International Gmbh Substituted bicyclic dihydropyrimidinones and their use as inhibitors of neutrophil elastase activity
PL3022202T3 (pl) 2013-07-18 2019-10-31 Novartis Ag Inhibitory autotaksyny zawierające heteroaromatyczny rdzeń pierścienia benzylowego - cyklicznego amidu
CN103724296B (zh) * 2013-12-12 2015-09-02 南京医科大学 芳基取代的哌嗪羰基衍生物及其制备方法和应用
WO2015186591A1 (fr) * 2014-06-06 2015-12-10 国立研究開発法人理化学研究所 Agent d'induction de cal et procédé d'induction de cal
CN105218501A (zh) * 2014-07-03 2016-01-06 南京大学 含哌嗪环的香豆素类衍生物及其制备与在抗菌药物中的应用
US9657015B2 (en) 2014-07-31 2017-05-23 Boehringer Ingelheim International Gmbh Substituted bicyclic dihydropyrimidinones and their use as inhibitors of neutrophil elastase activity
US9475779B2 (en) 2014-07-31 2016-10-25 Boehringer Ingelheim International Gmbh Substituted bicyclic dihydropyrimidinones and their use as inhibitors of neutrophil elastase activity
JP6749002B2 (ja) 2014-10-08 2020-09-02 国立研究開発法人理化学研究所 植物成長促進剤及び植物成長促進方法
AU2016275764B8 (en) 2015-06-11 2021-03-04 Basilea Pharmaceutica International AG Efflux-pump inhibitors and therapeutic uses thereof
WO2017214299A1 (fr) 2016-06-07 2017-12-14 Nanopharmaceuticals, Llc Polymère non clivable conjugué avec des antagonistes thyroïdiens de l'intégrine αvβ3
US11548893B2 (en) 2017-07-15 2023-01-10 Arisan Therapeutics Inc. Enantiomerically pure adamantane carboxamides for the treatment of filovirus infection
US11351137B2 (en) 2018-04-11 2022-06-07 Nanopharmaceuticals Llc Composition and method for dual targeting in treatment of neuroendocrine tumors
US10328043B1 (en) 2018-04-11 2019-06-25 Nanopharmaceuticals, Llc. Composition and method for dual targeting in treatment of neuroendocrine tumors
CN110372638B (zh) * 2018-04-13 2023-09-22 中国药科大学 哌嗪类ampk激动剂及其医药用途
CN108484558A (zh) * 2018-05-14 2018-09-04 中国药科大学 黄酮类ampk激动剂及其医药用途
US10961204B1 (en) 2020-04-29 2021-03-30 Nanopharmaceuticals Llc Composition of scalable thyrointegrin antagonists with improved blood brain barrier penetration and retention into brain tumors
EP4351650A1 (fr) * 2021-06-07 2024-04-17 NanoPharmaceuticals LLC Composition et méthode de double ciblage dans le traitement de tumeurs neuroendocrines
EP4115885A1 (fr) 2021-07-05 2023-01-11 Charité - Universitätsmedizin Berlin Composition pharmaceutique comprenant la baie 86-5277 et ses sels pour utilisation dans le traitement des infections virales et des hyperinflammations
US11723888B2 (en) 2021-12-09 2023-08-15 Nanopharmaceuticals Llc Polymer conjugated thyrointegrin antagonists
WO2023235297A1 (fr) * 2022-06-03 2023-12-07 Imbria Pharmaceuticals, Inc. Composés et méthodes pour augmenter l'efficacité du métabolisme cardiaque

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3324117A (en) 1967-06-06 Carboxylic acid piperazides and process for their manufacture
FR7524M (fr) 1968-03-12 1969-12-15
DE2304155A1 (de) * 1973-01-29 1974-08-01 Ichthyol Ges Cordes Hermanni & N-acylierte substituierte piperazinbzw. homopiperazinderivate, sowie verfahren zu ihrer herstellung
DE2730174C2 (de) 1977-07-04 1981-12-10 Ludwig Merckle Kg Chem. Pharm. Fabrik, 7902 Blaubeuren Aminobenzoesäurederivate und Arzneimittel enthaltend solche Aminobenzoesäurederivate
DE3060330D1 (en) * 1979-04-06 1982-06-09 Bayer Ag Azolyloxy-acetamides, process for their preparation and their use as herbicides
IT1151532B (it) 1982-03-29 1986-12-24 Ravizza Spa Procedimento per la preparazione di p. clorofenossiacetil-piperonilpiperazina
IT1151533B (it) 1982-03-29 1986-12-24 Ravizza Spa Procedimento per la preparazione di p. clorofenossiacetil-piperonilpiperazina
US4439606A (en) * 1982-05-06 1984-03-27 American Cyanamid Company Antiatherosclerotic 1-piperazinecarbonyl compounds
EP0190685B1 (fr) 1985-02-04 1992-07-01 G.D. Searle & Co. Amides hétérocycliques
DE3614363A1 (de) * 1986-04-28 1987-10-29 Hoechst Ag Benzothiazinon-derivate, verfahren zu ihrer herstellung, sie enthaltende arzneimittel und deren verwendung
JPS6314774A (ja) 1986-07-07 1988-01-21 Mitsubishi Chem Ind Ltd ピリダジノン誘導体又はその塩類
CN1030415A (zh) 1987-02-20 1989-01-18 山之内制药株式会社 饱和的杂环碳酰胺衍生物和它的制备方法
FR2611713B1 (fr) 1987-02-27 1990-11-30 Adir Nouveaux derives de l'acide (dihydro-2,3 oxo-2 benzofurannyl-3)-2 acetique, leurs procedes de preparation et les compositions pharmaceutiques qui les contiennent
EP0284632A1 (fr) 1987-03-30 1988-10-05 Shosuke Okamoto Dérivé de phénylalanine et inhibiteur de protéinase
CS260089B1 (cs) 1987-05-12 1988-11-15 Miroslav Protiva Piperazidy methoxyfenoxyoctových kyselin a jejich hydrochloridy
AT389112B (de) 1987-10-08 1989-10-25 Hoechst Ag Benzothiazinon-derivate, verfahren zu ihrer herstellung, sie enthaltende arzneimittel und deren verwendung
FR2623808B1 (fr) 1987-12-01 1990-03-09 Adir Nouveaux derives flavonoides (benzyl-4 piperazinyl-1)-2 oxo-2 ethylene substitues, leurs procedes de preparation et les compositions pharmaceutiques qui les contiennent
US5232923A (en) * 1988-03-18 1993-08-03 Mitsui Toatsu Chemicals, Incorporated Catechol derivatives and pharmaceutical preparations containing same
NZ228329A (en) 1988-03-18 1991-12-23 Mitsui Toatsu Chemicals Catechol derivatives and pharmaceutical compositions thereof
US5010080A (en) 1988-12-02 1991-04-23 G. D. Searle & Co. Use of heterocyclic amides to inhibit tumor metastasis
US5089506A (en) * 1990-04-30 1992-02-18 G. D. Searle & Co. Ethanobicyclic amine derivatives for cns disorders
US5190922A (en) 1991-06-04 1993-03-02 Abbott Laboratories Terminally modified tri-, tetra- and pentapeptide anaphylatoxin receptor ligands
FR2689127B1 (fr) * 1992-03-31 1994-05-06 Adir Cie Nouvelles 3', 5' -ditertbutyl-4'-hydroxy flavones, leur procede de preparation et les compositions pharmaceutiques les renfermant.
US5272175A (en) 1992-05-20 1993-12-21 G. D. Searle & Co. Substituted tyrosyl diamide compounds
US5389645A (en) 1992-08-13 1995-02-14 G. D. Searle & Co. Substituted tyrosyl diamine amide compounds
HUT70475A (en) 1992-09-03 1995-10-30 Boehringer Ingelheim Kg New aminoacid derivates, process for producing the same and pharmaceutical compositions containing these compounds
IL110040A (en) 1993-06-29 2000-07-16 Nissan Chemical Ind Ltd Pyridazinone derivatives their preparation and pharmaceutical compositions comprising them
KR100196356B1 (ko) 1993-09-28 1999-06-15 오스카 아끼히꼬 당뇨병 치료제
IL111730A (en) 1993-11-29 1998-12-06 Fujisawa Pharmaceutical Co Piperazine derivatives, processes for their preparation and pharmaceutical preparations containing them
FR2724656B1 (fr) 1994-09-15 1996-12-13 Adir Nouveaux derives du benzopyranne, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
WO1996034864A1 (fr) 1995-05-02 1996-11-07 Schering Corporation Derives piperazino en tant qu'antagonistes des neurokinines
WO1998002151A2 (fr) 1996-07-12 1998-01-22 Leukosite, Inc. Antagonistes des recepteurs de la chemokine et procedes d'utilisation de ces derniers
AU3633997A (en) * 1996-07-29 1998-02-20 Banyu Pharmaceutical Co., Ltd. Chemokine receptor antagonists
KR100447553B1 (ko) * 1997-02-26 2004-09-08 화이자 인코포레이티드 헤테로아릴-헥사노산 아미드 유도체, 그의 제조 방법 및 ｍｉｐ-1 알파의 ｃｃｒ1 수용체로의 결합에 대한 선택적 저해제로서의 용도
US6207665B1 (en) * 1997-06-12 2001-03-27 Schering Aktiengesellschaft Piperazine derivatives and their use as anti-inflammatory agents
BR0104424A (pt) 2000-02-05 2002-01-08 Vertex Pharma Composições de pirazol úteis como inibidores de erk
US6521619B2 (en) * 2000-06-29 2003-02-18 Icos Corporation Aryl phenylcyclopropyl sulfide derivatives and their use as cell adhesion inhibiting anti-inflammatory and immune suppressive agents
US6518276B2 (en) 2000-08-31 2003-02-11 Syntex (U.S.A.) Llc 7-oxo-pyridopyrimidines (II)

Also Published As

Publication number Publication date
DE69830341T2 (de) 2006-02-02
EP0988292A2 (fr) 2000-03-29
IS2241B (is) 2007-05-15
NO996068L (no) 2000-02-11
SK285445B6 (sk) 2007-01-04
EP0988292B1 (fr) 2003-02-12
EA004038B1 (ru) 2003-12-25
DK0988292T3 (da) 2003-04-22
US6207665B1 (en) 2001-03-27
CZ295784B6 (cs) 2005-11-16
EA200200262A1 (ru) 2002-06-27
NO996068D0 (no) 1999-12-09
EP1254899B1 (fr) 2005-05-25
EP1254899A2 (fr) 2002-11-06
IS5258A (is) 1999-11-19
US6977258B2 (en) 2005-12-20
EE04056B1 (et) 2003-06-16
EA199901063A1 (ru) 2001-04-23
US20060135487A1 (en) 2006-06-22
CA2293382A1 (fr) 1998-12-17
EE200200683A (et) 2003-04-15
US6541476B1 (en) 2003-04-01
PL337758A1 (en) 2000-09-11
US20020177598A1 (en) 2002-11-28
HUP0003929A2 (hu) 2001-05-28
EP1254899A3 (fr) 2003-02-19
DE69811363T2 (de) 2003-11-27
DE69830341D1 (de) 2005-06-30
KR20010013703A (ko) 2001-02-26
NO20031373D0 (no) 2003-03-26
EE200200682A (et) 2003-04-15
NO317343B1 (no) 2004-10-11
JP2002503239A (ja) 2002-01-29
HUP0003929A3 (en) 2001-08-28
KR100549137B1 (ko) 2006-02-03
IL132398A0 (en) 2001-03-19
AU8625898A (en) 1998-12-30
ES2191320T3 (es) 2003-09-01
US20030158205A1 (en) 2003-08-21
IL132398A (en) 2004-08-31
US20030139425A1 (en) 2003-07-24
US6972290B2 (en) 2005-12-06
EE200200684A (et) 2003-04-15
ATE232522T1 (de) 2003-02-15
US7268140B2 (en) 2007-09-11
DE69811363D1 (de) 2003-03-20
US6534509B1 (en) 2003-03-18
US6555537B2 (en) 2003-04-29
SK285162B6 (sk) 2006-07-07
NO20031373L (no) 2000-02-11
PT1254899E (pt) 2005-10-31
CZ448199A3 (cs) 2000-04-12
US6573266B1 (en) 2003-06-03
TR199903034T2 (xx) 2000-06-21
SK171399A3 (en) 2000-09-12
ES2242824T3 (es) 2005-11-16
AU735462B2 (en) 2001-07-12
EE9900565A (et) 2000-06-15
ATE296292T1 (de) 2005-06-15
WO1998056771A3 (fr) 1999-03-11
WO1998056771A2 (fr) 1998-12-17
CA2293382C (fr) 2008-03-11

Similar Documents

Publication Publication Date Title
DK0988292T3 (da) Piperazinderivater og deres anvendelse som antiinflammationsmidler
YU14495A (sh) Jedinjenja koja su prolekovi antagonista morfolin tahikininskih receptora i njihove farmaceutske kompozicije
TR200201505T2 (tr) Terapötik maddeler olarak pirazolopirimidinler
PT967214E (pt) Formulacoes intranasais para o tratamento de desordens sexuais
PT896533E (pt) Pentafluorobenzenosulfonamidas e analogos
ATE253063T1 (de) 5-ht1f-agonisten
DK1097173T3 (da) Anvendelse af peptider af IL-2 og derivater deraf som terapeutiske midler
BR9907655A (pt) Derivados de ácido di-hidróxi-hexanóico
AR020563A1 (es) Compuestos (poli)tia-alquinoicos y sus derivados, composiciones que los incluyen y su utilizacion
SE9801494D0 (sv) Novel use
DE59909607D1 (de) Tan-1057 derivate
DK0916670T3 (da) Pyrrolo[3,2-b]pyridiner og deres anvendelse som 5-HT1f-agonister
BR0007183A (pt) Isonipectoamidas para o tratamento de distúrbios mediados por integrina
TR200400270T4 (tr) Birleşik pirol bileşikleri, içerildikleri farmasötik maddeler ve bunların kullanımları.